MedTrace Logo

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2026-01-16

No results posted yet for this study

Summary

The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.

Conditions

Interventions

DIAGNOSTIC_TEST

Clinical tau PET

Tau PET (flortaucipir)

DIAGNOSTIC_TEST

Clinical amyloid test

Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test

OTHER

Research blood collection

Research blood assays for amyloid, tau, and neurodegeneration

OTHER

Cognitive assessments

Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Randall Bateman, MD · Washington University School of Medicine

  • David Carr, MD · Washington University School of Medicine

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-14
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06547099 on ClinicalTrials.gov